Literature DB >> 18415209

[Oral opioids in patients with non-malignant pain.].

M Zenz1, M Strumpf, A Willweber-Strumpf.   

Abstract

Opioids are given for acute intra- and postope-rative pain relief or for chronic cancer pain. In the literature there are only rare and contradictory reports on the oral administration of opioids for chronic non-malignant pain. However, there is no reason to withhold strong analgesics for patients with severe pain. When all other thrapeutic measures fail to control pain, patients with non-malignant pain can also be treated by opioids. We report 70 patients with severe pain who were given opioids as the ultima ratio in pain therapy: 50 received buprenorphine sublingual tablets, 13 received morphine sustained release tablets and the remaining 7 were treated with other opioids. The mean daily dose was 1.45 mg buprenorphine or 87.6 mg morphine. The dosage increased in 12 of the 50 patients treated with buprenorphine while 5 of the 13 morphine patients needed increasing dosage. The other patients had a constant dosage after the initial period of dose-finding. In more than 50% the pain could be effectively controlled by oral opioids. The general performance status (Karnofsky) increased from 63.6% to 74.1%. The typical side effects were constipation and nausea. Prophylaxis of constipation is most important during opioid therapy. No case of respiratory depression or opioid addiction was registered. Our results show that patients with musculo-skeletal and deafferentation pain respond better to opioids than patients with headache. Negative results were observed in some patients with neuropathic pain. The results of the study show that opioids are justifiable for the treatment of non-malignant pain and can be given without danger over a long period of time. Side effects are controlled by additional medication. The principle of opioid administration is prophylaxis of pain -therefore, they should be given "by the clock". Opioids are not only indicated in malignant illness, but also according to severity of pain and by the failure of other measures to control pain.

Entities:  

Year:  1990        PMID: 18415209     DOI: 10.1007/BF02527825

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  25 in total

1.  [Not Available].

Authors:  W Keup
Journal:  Schmerz       Date:  1988-09       Impact factor: 1.107

2.  [Not Available].

Authors:  M Mumenthaler
Journal:  Schmerz       Date:  1988-03       Impact factor: 1.107

3.  [Long-term therapy of cancer pain. A controlled study on buprenorphine].

Authors:  M Zenz; S Piepenbrock; M Tryba; M Glocke; M Everlien; W Klauke
Journal:  Dtsch Med Wochenschr       Date:  1985-03-22       Impact factor: 0.628

4.  The myth of haloperidol potentiation.

Authors:  G W Hanks; P J Thomas; T Trueman; E Weeks
Journal:  Lancet       Date:  1983-08-27       Impact factor: 79.321

5.  Can opiates relieve neuropathic pain?

Authors:  Howard L Fields
Journal:  Pain       Date:  1988-12       Impact factor: 6.961

6.  Addiction rare in patients treated with narcotics.

Authors:  J Porter; H Jick
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

7.  Chronic intractable pain: an atypical presentation of multiple sclerosis.

Authors:  R K Portenoy; K Yang; D Thorton
Journal:  J Neurol       Date:  1988-03       Impact factor: 4.849

8.  [Use of oral morphine in incurable pain].

Authors:  R Twycross; M Zenz
Journal:  Anaesthesist       Date:  1983-06       Impact factor: 1.041

9.  Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain.

Authors:  S Arnér; B A Meyerson
Journal:  Pain       Date:  1988-04       Impact factor: 6.961

10.  Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.

Authors:  Russell K Portenoy; Kathleen M Foley
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

View more
  21 in total

1.  [Not Available].

Authors:  M Zimmermann
Journal:  Schmerz       Date:  1990-09       Impact factor: 1.107

2.  [Not Available].

Authors:  M Zenz; M Strumpf; A Willweber-Strumpf
Journal:  Schmerz       Date:  1991-06       Impact factor: 1.107

3.  [Not Available].

Authors:  C Maier; J Hildebrandt; C Maier
Journal:  Schmerz       Date:  1991-06       Impact factor: 1.107

4.  [Not Available].

Authors:  M Zimmermann
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

5.  [Not Available].

Authors:  B Kossmann; U Thoden
Journal:  Schmerz       Date:  1991-06       Impact factor: 1.107

6.  [Not Available].

Authors:  D Zech
Journal:  Schmerz       Date:  1991-06       Impact factor: 1.107

7.  [Not Available].

Authors:  R Wörz
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

8.  [To give or not to give, that is not the question here! Longterm administration of opioids for non-tumor pain (LONTS)].

Authors:  T R Tölle; R-D Treede; M Zenz
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

9.  [Long-term application of opioids in chronic noncancer pain (LONTS 2): Urgently required new guidelines].

Authors:  R-D Treede; M Zenz
Journal:  Schmerz       Date:  2015-02       Impact factor: 1.107

10.  [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine].

Authors:  H Göbel; T Stadler
Journal:  Drugs       Date:  1997       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.